Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.

[1]  A. Aplin,et al.  Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. , 2015, Cancer research.

[2]  H. Rui,et al.  Expression of insulin‐like growth factor‐1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth , 2014, Pigment cell & melanoma research.

[3]  Zhiwei Wang,et al.  Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. , 2013, European journal of cancer.

[4]  A. Mercurio,et al.  VEGF targets the tumour cell , 2013, Nature Reviews Cancer.

[5]  J. Burnier,et al.  Vascular endothelial growth factor expression and inhibition in uveal melanoma cell lines , 2013, ecancermedicalscience.

[6]  Roman K. Thomas,et al.  Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. , 2013, The Journal of clinical investigation.

[7]  Martin Peifer,et al.  Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer , 2013 .

[8]  H. Grossniklaus.  Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture. , 2013, JAMA ophthalmology.

[9]  M. Burnier,et al.  Uveal melanoma dormancy: an acceptable clinical endpoint? , 2012, Melanoma research.

[10]  M. Hendrix,et al.  Molecular Pathways: Vasculogenic Mimicry in Tumor Cells: Diagnostic and Therapeutic Implications , 2012, Clinical Cancer Research.

[11]  V. Barak,et al.  VEGF as a biomarker for metastatic uveal melanoma in humans. , 2011, Current eye research.

[12]  Shaorong Zhao,et al.  Inhibition of tumor growth and vasculogenic mimicry by curcumin through down-regulation of the EphA2/PI3K/MMP pathway in a murine choroidal melanoma model , 2011, Cancer biology & therapy.

[13]  A. Bowcock,et al.  Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas , 2010, Science.

[14]  M. Abdel-Rahman,et al.  MET oncogene inhibition as a potential target of therapy for uveal melanomas. , 2010, Investigative ophthalmology & visual science.

[15]  S. Mizuno,et al.  The discovery of Hepatocyte Growth Factor (HGF) and its significance for cell biology, life sciences and clinical medicine , 2010, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[16]  G. Luyten,et al.  Regulation of VEGF-A in uveal melanoma. , 2010, Investigative ophthalmology & visual science.

[17]  F. Söylemezoğlu,et al.  Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma , 2010, Melanoma research.

[18]  A. Aplin,et al.  FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells. , 2010, Cancer research.

[19]  Morag Park,et al.  Crosstalk in Met receptor oncogenesis. , 2009, Trends in cell biology.

[20]  Li Yang,et al.  Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells , 2009, Journal of experimental & clinical cancer research : CR.

[21]  Baocun Sun,et al.  Chimerism and central , 1996 .

[22]  Susan Muller,et al.  KIT Gene Mutations and Copy Number in Melanoma Subtypes , 2008, Clinical Cancer Research.

[23]  Takami Sato,et al.  The biology and management of uveal melanoma , 2008, Current oncology reports.

[24]  K. Bartz-Schmidt,et al.  Visualization of Circulating Melanoma Cells in Peripheral Blood of Patients with Primary Uveal Melanoma , 2008, Clinical Cancer Research.

[25]  H. Grossniklaus,et al.  In-vivo xenograft murine human uveal melanoma model develops hepatic micrometastases , 2008, Melanoma research.

[26]  D. Faingold,et al.  Molecular Pathways Mediating Liver Metastasis in Patients with Uveal Melanoma , 2008, Clinical Cancer Research.

[27]  R. Folberg,et al.  Modeling the behavior of uveal melanoma in the liver. , 2007, Investigative ophthalmology & visual science.

[28]  E. Antecka,et al.  Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study , 2007, Eye.

[29]  Y. Huang,et al.  Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo , 2007, International Journal of Gynecologic Cancer.

[30]  M. Weiser,et al.  Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met–expressing tumors , 2007, Molecular Cancer Therapeutics.

[31]  E. Thiel,et al.  Circulating Tumor Cells as Prognostic Factor for Distant Metastases and Survival in Patients with Primary Uveal Melanoma , 2007, Clinical Cancer Research.

[32]  K. Mallikarjuna,et al.  Expression of Epidermal Growth Factor Receptor, Ezrin, Hepatocyte Growth Factor, and c-Met in Uveal Melanoma: An Immunohistochemical Study , 2007, Current eye research.

[33]  P. Eilers,et al.  Vascular endothelial growth factor a in eyes with uveal melanoma. , 2006, Archives of ophthalmology.

[34]  R. Mangues,et al.  Mouse models in oncogenesis and cancer therapy , 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[35]  K. Mallikarjuna,et al.  Expression of Insulin-Like Growth Factor Receptor (IGF-1R), c-Fos, and c-Jun in Uveal Melanoma: An Immunohistochemical Study , 2006, Current Eye Research.

[36]  J. Keunen,et al.  Angiogenic Profile of Uveal Melanoma , 2006, Current eye research.

[37]  O. Larsson,et al.  Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. , 2005, Investigative ophthalmology & visual science.

[38]  J. Joyce,et al.  Therapeutic Targeting of the Tumor Microenvironment. , 2021, Cancer discovery.

[39]  N. Hayward,et al.  Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS , 2005, British Journal of Cancer.

[40]  Arun D. Singh,et al.  Uveal melanoma: epidemiologic aspects. , 2005, Ophthalmology clinics of North America.

[41]  G. Woude,et al.  Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor , 2005, Oncogene.

[42]  M. Kotb,et al.  Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2Rγnull Mice Engrafted with Mobilized Human Hemopoietic Stem Cells 12 , 2004, The Journal of Immunology.

[43]  N. Fusenig,et al.  Friends or foes — bipolar effects of the tumour stroma in cancer , 2004, Nature Reviews Cancer.

[44]  D. Morton,et al.  Prolonged survival after complete resection of metastases from intraocular melanoma , 2004, Cancer.

[45]  T. Kivelä,et al.  Very long-term prognosis of patients with malignant uveal melanoma. , 2003, Investigative ophthalmology & visual science.

[46]  D. Speiser,et al.  Lack of BRAF mutations in uveal melanoma. , 2003, Cancer research.

[47]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[48]  M. Hendrix,et al.  Angiogenesis: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma , 2003, Nature Reviews Cancer.

[49]  R. E. Kalina,et al.  Immunophenotype of conjunctival melanomas: comparisons with uveal and cutaneous melanomas. , 2002, Archives of ophthalmology.

[50]  R. Folberg,et al.  An orthotopic model for human uveal melanoma in SCID mice. , 2002, Microvascular research.

[51]  M. Yaffe.  Faculty Opinions recommendation of Mutations of the BRAF gene in human cancer. , 2002 .

[52]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[53]  D. Ruiter,et al.  Presence of a fluid-conducting meshwork in xenografted cutaneous and primary human uveal melanoma. , 2002, Investigative ophthalmology & visual science.

[54]  R. E. Kalina,et al.  Immunophenotypic differences between uveal and cutaneous melanomas. , 2002, Archives of ophthalmology.

[55]  R S McCuskey,et al.  Morphological mechanisms for regulating blood flow through hepatic sinusoids. , 2000, Liver.

[56]  R Folberg,et al.  Vasculogenic mimicry and tumor angiogenesis. , 2000, The American journal of pathology.

[57]  I. Fidler,et al.  Orthotopic Models are Necessary to Predict Therapy of Transplantable Tumors in Mice , 1998, Cancer and Metastasis Reviews.

[58]  M. Burnier,et al.  Uveal melanoma: Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size , 1997 .

[59]  D. Le Roith,et al.  Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. , 1997 .

[60]  I. Fidler.  Critical determinants of melanoma metastasis. , 1996, The journal of investigative dermatology. Symposium proceedings.

[61]  Division on Earth.  Guide for the Care and Use of Laboratory Animals , 1996 .

[62]  N. Bornfeld,et al.  Prognosis and treatment of disseminated uveal melanoma , 1993, Cancer.

[63]  R. Folberg,et al.  The prognostic value of tumor blood vessel morphology in primary uveal melanoma. , 1993, Ophthalmology.

[64]  R. Folberg,et al.  The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. , 1992, Human pathology.

[65]  R. Glynn,et al.  Survival of patients with metastases from uveal melanoma. , 1991, Ophthalmology.

[66]  G. Barsh,et al.  Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi , 2010 .

[67]  A. Bedikian.  Metastatic Uveal Melanoma Therapy: Current Options , 2006, International ophthalmology clinics.

[68]  Robert M. Hoffman,et al.  Orthotopic Metastatic Mouse Models for Anticancer Drug Discovery and Evaluation: a Bridge to the Clinic , 2004, Investigational New Drugs.

[69]  R. Scully,et al.  Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. , 2001, Archives of ophthalmology.

[70]  D. Le Roith.  Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. , 1997, The New England journal of medicine.